Innate immune sensing and vaccine strategies against West Nile virus: role of Toll-like receptors and viral evasion mechanisms

TL;DR

This paper reviews how the body's innate immune system, particularly Toll-like receptors, responds to West Nile virus and discusses vaccine strategies to combat it.

Contribution

The paper provides a comprehensive review of TLR-mediated immunity and vaccine development for WNV, emphasizing TLR agonists as potential adjuvants.

Findings

TLRs are crucial for detecting WNV and initiating immune responses.

WNV evades immune detection through various mechanisms.

TLR agonists show promise as adjuvants in WNV vaccine development.

Abstract

The West Nile virus (WNV), an emerging neurotropic flavivirus and a leading cause of viral encephalitis worldwide, represents a significant public health threat owing to its neuroinvasive potential and the absence of a licensed human vaccine. Understanding the host immune response to WNV, particularly the role of Toll-like receptors (TLRs), is critical for elucidating viral pathogenesis and developing therapeutic strategies. TLRs are essential for the detection of viral components, initiation of innate immunity, and shaping of adaptive responses. Despite progress in research, no clinically approved WNV vaccine is currently available for humans, highlighting the urgent need for effective vaccine development. This review summarizes the current knowledge regarding the TLR-mediated immunity in WNV infection, with a focus on immune activation mechanisms and viral evasion strategies. Furthermore, we examine recent advances in vaccine development, emphasizing the potential of TLR agonists as adjuvants to enhance immunogenicity and protective efficacy.

Figures